Mostrar el registro sencillo del ítem

dc.contributor.authorCarreño, Fernandopt_BR
dc.contributor.authorPaese, Karinapt_BR
dc.contributor.authorSilva, Carolina de Mirandapt_BR
dc.contributor.authorGuterres, Silvia Stanisçuaskipt_BR
dc.contributor.authorDalla Costa, Teresa Cristina Tavarespt_BR
dc.date.accessioned2017-02-18T02:42:44Zpt_BR
dc.date.issued2015pt_BR
dc.identifier.issn0100-4042pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/152723pt_BR
dc.description.abstractQuetiapine is an atypical antipsychotic used to treat schizophrenia. However, despite great interest for its chronic therapeutic use, quetiapine has some important side effects such as weight gain induction. The development of a quetiapine nanocarrier can potentially target the drug into central nervous system, resulting in a reduction of systemic side effects and improved patient treatment. In the present work, a simple liquid chromatography/ultraviolet detection (LC/UV) analytical method was developed and validated for quantification of total quetiapine content in lipid core nanocapsules as well as for determination of incorporation efficiency. An algorithm proposed by Oliveira et al. (2012) was applied to characterize the distribution of quetiapine in the pseudo-phases of the nanocarrier, leading to a better understanding of the quetiapine nanoparticles produced. The analytical methodology developed was specific, linear in the range of 0.5 to 100 µg mL−1 (r2 > 0,99), and accurate and precise (R.S.D < ±5%). The absolute recovery of quetiapine from the nanoparticles was approximately 98% with an incorporation efficiency of approximately 96%. The results indicated that quetiapine was present in a type III distribution according to the algorithm, and was mainly located in the core of the nanoparticle because of its logD in the formulation pH (6.86 ± 0.4).en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofQuímica nova. São Paulo, SP. Vol. 38, n. 9 (2015), p. 1181-1186pt_BR
dc.rightsOpen Accessen
dc.subjectAntipsicóticospt_BR
dc.subjectQuetiapineen
dc.subjectLipid core nanocapsulesen
dc.subjectFármacospt_BR
dc.subjectHPLC/UVen
dc.subjectAnalytical method validationen
dc.titleCharacterizing the mechanism of quetiapine distribution in lipid-core nanocapsules pseudo-phases using a validated LC/UV methodpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001010865pt_BR
dc.type.originNacionalpt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem